DDInter1201 DDInter1747
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue. Administration of metreleptin results in improvement of metabolic symptoms including improvements in insulin resistance, reduced HbA1c and fasting glucose, reduced triglycerides, and reductions in food intake. Metreleptin is produced in _E. coli_ and differs from native human leptin by the addition of a methionine residue at its amino terminus. In February
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Metreleptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Metreleptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Metreleptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Metreleptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Metreleptin {u} may lead to a major life threatening interaction when taken with {v} Lumateperone
Metreleptin may cause a minor interaction that can limit clinical effects when taken with Relugolix
Metreleptin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Metreleptin may lead to a major life threatening interaction when taken with Lumateperone